Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics reported final pivotal Phase III efficacy results showing strong outcomes on eGFR and a kidney composite endpoint, while its newly launched therapy generated more than 350 patient-start forms in roughly 10 weeks. The company plans to submit an sBLA in Q4 2026, targeting full approval by mid-2027. Management expects to present the expanded data set at the ASN kidney conference next month, supporting both commercial uptake and the regulatory pathway.

Analysis

VERA’s valuation will now hinge less on binary clinical proof and more on conversion efficiency: start forms must translate into paid starts, persistence, and manageable gross-to-net discounts. The early prescription signal is directionally constructive, but it is not yet a revenue run-rate; specialty-pharmacy fulfillment, prior-authorization approval rates, and discontinuations will determine whether consensus can justify a premium rare-disease launch multiple over the next 1-3 quarters.

The competitive read-through is most negative for TVTX, whose Filspari franchise depends on establishing durable physician and payer preference before a potentially differentiated immunology-based alternative broadens its label. A full-approval pathway could improve payer confidence and reduce perceived regulatory-duration risk for VERA, but it also raises the commercial bar: nephrologists may reserve treatment for higher-risk patients unless the detailed dataset demonstrates a clear benefit across baseline proteinuria and eGFR strata. The key 6-18 month upside is earlier-line adoption; the key near-term risk is that uptake remains concentrated in academic centers.

The October ASN presentation is the first genuine catalyst because it allows investors to test whether the kidney-function and composite-endpoint results are clinically robust rather than management-selected. FDA timing remains a meaningful binary risk: an sBLA filing, acceptance, and eventual approval are separate events, and safety, CMC, or durability questions could delay the mid-2027 target. Thesis is falsified if paid-start conversion is weak by the next earnings update, gross-to-net proves materially higher than expected, or detailed data fail to establish a credible differentiation versus existing IgAN therapies.

Key Decisions for Investors

• Establish only a starter long VERA ahead of ASN, sized as an event position rather than a full commercial-launch underwriting. Add only if detailed data show consistent eGFR/composite benefit across clinically relevant subgroups and management discloses paid-start or fulfillment metrics; reduce if the presentation exposes subgroup fragility or a safety imbalance.
• Use a 1-3 month relative-value watch: long VERA / short TVTX becomes actionable only after checking relative valuations, short availability, and overlap in payer access. The trade works if VERA’s mechanism shifts physician sequencing toward earlier immunologic intervention; it fails if Filspari’s real-world persistence and payer entrenchment remain materially stronger.
• Do not annualize patient-start forms into revenue. Set an alert for the next quarterly update on conversion from forms to paid starts, time to therapy, discontinuation, and gross-to-net; these metrics are required before raising a revenue model or treating the launch as de-risked.
• For holders, retain regulatory downside protection into the Q4 sBLA submission/acceptance window through defined-risk puts or a collar if implied volatility is reasonable. A filing acceptance is a de-risking catalyst, but it does not eliminate the larger mid-2027 approval, labeling, and manufacturing-risk event.